Li, Sienna R.
Gulieva, Ramila E.
Helms, Louisa
Cruz, Nelly M.
Vincent, Thomas
Fu, Hongxia
Himmelfarb, Jonathan
Freedman, Benjamin S. http://orcid.org/0000-0003-2228-7383
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01DK117914)
Article History
Received: 30 October 2022
Accepted: 8 December 2022
First Online: 23 December 2022
Competing interests
: N.M.C. and B.S.F. are inventors on patents and/or patent applications related to human kidney organoid differentiation and modeling of PKD in this system (these include “Three-dimensional differentiation of epiblast spheroids into kidney tubular organoids modeling human microphysiology, toxicology, and morphogenesis” [Japan, US, and Australia], licensed to STEMCELL Technologies; “High-throughput automation of organoids for identifying therapeutic strategies” [PTC patent application pending]; “Systems and methods for characterizing pathophysiology” [PTC patent application pending]). B.S.F. and H.F. have ownership interest in Plurexa LLC. None of the preceding interests affected in any way the results of the paper or would be affected by them, but they are shared by way of transparency. All other authors declare no competing interests.